CD40 and melanoma: In immunologically “hot” tumors like melanoma, where considerable immune infiltration is prevalent, the triggering of the adaptive immune responses through anti-CD40-mAb may not add any additional benefit, but it can add an advantage to “cold” tumors like TNBCs.